SCHEMBL20072694

SCHEMBL20072694

CCCCCCCCCCCCOC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.55
TK2 O00142 8/20 0.49
TK1 P04183 1/20 0.47
HRH4 Q9H3N8 1/20 0.46
LTA4H P09960 1/20 0.46
TSHR P16473 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
PLA2G2A P14555 2/20 0.41
PLA2G10 O15496 1/20 0.41
PLA2G1B P04054 1/20 0.41
PLA2G5 P39877 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
MLNR O43193 1/20 0.40
NR1I2 O75469 1/20 0.40
ESR1 P03372 1/20 0.40
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11503704 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL21411547 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL8142505 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL4803716 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL25077100 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL5820308 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL25077435 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL5820348 1.00 KIF11 (0.55) KIF11TK2TK1HRH4LTA4H
SCHEMBL17243243 0.98 KIF11 (0.57) KIF11TK2TK1HRH4LTA4H
SCHEMBL4478143 0.93 KIF11 (0.49) KIF11TK2TK1HRH4LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10456473-B2 Lipid compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2019-10-29 US disclosed
US-20180104342-A1 LIPID COMPOSITIONS ARBUTUS BIOPHARMA CORPORATION (CA) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180104342-A1 LIPID COMPOSITIONS SGMS1, LIPA, SGMS2 KIF11 2959/4885TK2 3371/4885TK1 3735/4885
US-10456473-B2 Lipid compositions SGMS1, LIPA, SGMS2 KIF11 2959/4885TK2 3371/4885TK1 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.